US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy

<html xmlns=""><head><title>UPDATE 3-US FDA panel backs Sanofi-AstraZeneca's preventive RSV therapy</title></head><body>

Adds comments from the meeting, background on Pfizer's vaccine in paragraphs 8-9

By Raghav Mahobe and Mariam Sunny

June 8 (Reuters) -The U.S. Food and Drug Administration advisers on Thursday backed the use of Sanofi SASY.PA and partner AstraZeneca's AZN.L experimental antibody to prevent respiratory syncytial virus (RSV) infections in infants.

The advisers voted unanimously in favor of using the antibody, nirsevimab, in newborns and infants to prevent infections in their first RSV season.

In a separate 19-2 vote, the panel backed the therapy's use in children aged up to two years who are vulnerable to severe illness through their second RSV season.

Swedish Orphan Biovitrum's SOBIV.ST treatment Synagis is currently the only approved preventive therapy in the United States for high-riskinfants against RSV, a leading cause of hospitalizations during an infant's first year of life.

Unlike Synagis, which is given as monthly injections, nirsevimab is a long-acting therapy expected to be given once every season to prevent infection regardless of additional medical conditions in infants.

"This is probably the closest thing to an RSV vaccine that we have and it really moves the field forward," said panel member NimishPatel.

Two studies showed the therapy was effective in preventing lower respiratory tract infections, the FDA staff reviewers had said on Tuesday.

The panel vote comes a few weeks after advisersto the FDA backed the use of Pfizer's PFE.N maternal vaccine, boosting its chances to become the first shot to protect infants from RSV. It is not known how the therapy works in infants whose mothers have received experimental RSV shots.

"I think there will need to be studies that are done to figure out when one is more useful than the other," panelist Karen Kotloff said.

Nirsevimab's peak sales are estimated to touch $2 billion, according to Morningstar analyst Dampen Conover.

The advisory panel provides non-binding recommendations to the FDA, which is expected to make a decision on the therapy by the third quarter.

Reporting by Mariam Sunny and Raghav Mahobe in Bengaluru; Editing by Maju Samuel


Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.